2vnm: Difference between revisions

From Proteopedia
Jump to navigationJump to search
Newer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
New page: left|200px <!-- The line below this paragraph, containing "STRUCTURE_2vnm", creates the "Structure Box" on the page. You may change the PDB parameter (which sets the PD...
 
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
Line 1: Line 1:
[[Image:2vnm.jpg|left|200px]]
{{Seed}}
[[Image:2vnm.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2vnm|  PDB=2vnm  |  SCENE=  }}  
{{STRUCTURE_2vnm|  PDB=2vnm  |  SCENE=  }}  


'''HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE'''
===HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE===




==Overview==
<!--  
BACE-1 inhibition has the potential to provide a disease-modifying therapy for the treatment of Alzheimer's disease. Optimization of a first generation of BACE-1 inhibitors led to the discovery of novel hydroxyethylamines (HEAs) bearing a tricyclic nonprime side. These derivatives have nanomolar cell potency and are orally bioavailable.
The line below this paragraph, {{ABSTRACT_PUBMED_18457381}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 18457381 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_18457381}}


==About this Structure==
==About this Structure==
Line 61: Line 65:
[[Category: Transmembrane]]
[[Category: Transmembrane]]
[[Category: Zymogen]]
[[Category: Zymogen]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu May 22 21:41:48 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 11:09:04 2008''
Retrieved from "https://proteopedia.org/2vnm"